Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

Hep B vac­cine mak­er Dy­navax has re­al­ized it needs por­tion con­trol be­cause there’s far too much on its plate.

On Thurs­day, the Cal­i­for­nia-based com­pa­ny said it need­ed to fo­cus all its re­sources on its 2017-ap­proved Hep­lisav-B and its broad­er vac­cine busi­ness, so it is ex­plor­ing strate­gic al­ter­na­tives for its im­muno-on­col­o­gy pro­grams and cut­ting jobs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER